argenx (NASDAQ:ARGX) Lifted to “Outperform” at Oppenheimer

Oppenheimer upgraded shares of argenx (NASDAQ:ARGX) from a market perform rating to an outperform rating in a report issued on Tuesday, MarketBeat.com reports. Oppenheimer currently has $546.00 price target on the stock.

Several other equities research analysts also recently commented on ARGX. William Blair reiterated a market perform rating on shares of argenx in a research report on Monday, June 17th. Scotiabank lifted their target price on shares of argenx from $402.00 to $408.00 and gave the stock a sector perform rating in a research report on Tuesday, March 26th. JPMorgan Chase & Co. lowered their price target on shares of argenx from $560.00 to $500.00 and set an overweight rating for the company in a report on Monday, May 13th. Bank of America restated a buy rating and set a $607.00 price target (up previously from $535.00) on shares of argenx in a report on Monday, June 24th. Finally, Stifel Nicolaus raised their price target on shares of argenx from $485.00 to $500.00 and gave the stock a buy rating in a report on Monday, June 24th. Three analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $535.37.

argenx Trading Up 4.7 %

ARGX opened at $486.33 on Tuesday. The company’s 50 day moving average is $413.06 and its 200-day moving average is $394.35. argenx has a 1-year low of $327.73 and a 1-year high of $532.59. The company has a market cap of $28.90 billion, a P/E ratio of -85.92 and a beta of 0.64.

argenx (NASDAQ:ARGX) last posted its earnings results on Monday, May 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.33). argenx had a negative return on equity of 14.14% and a negative net margin of 22.58%. The business had revenue of $412.51 million for the quarter, compared to analyst estimates of $404.03 million. During the same quarter in the prior year, the business earned ($0.52) earnings per share. On average, equities analysts forecast that argenx will post -2.93 EPS for the current year.

Institutional Trading of argenx

Hedge funds have recently bought and sold shares of the business. J.Safra Asset Management Corp grew its position in argenx by 590.0% in the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after purchasing an additional 59 shares during the period. Blue Trust Inc. boosted its holdings in argenx by 620.0% during the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after acquiring an additional 62 shares during the last quarter. GAMMA Investing LLC boosted its holdings in argenx by 420.0% during the 1st quarter. GAMMA Investing LLC now owns 78 shares of the company’s stock worth $31,000 after acquiring an additional 63 shares during the last quarter. Mather Group LLC. purchased a new position in argenx during the 1st quarter worth $38,000. Finally, Benjamin F. Edwards & Company Inc. purchased a new position in argenx during the 4th quarter worth $60,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.